Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

June 7, 2023

Study Completion Date

June 8, 2023

Conditions
Chronic Ocular Pain
Interventions
OTHER

SAF312 Placebo

Topical ocular, suspension eye drops

DRUG

SAF312

Topical ocular, suspension eye drops

Trial Locations (28)

19104

University of Pennsylvania ., Philadelphia

24502

Piedmont Eye Center, Lynchburg

27710

Duke Univ Medical Center Ophthalmology, Durham

32256

Novartis Investigative Site, Jacksonville

33067

Novartis Investigative Site, Coral Springs

33136

Novartis Investigative Site, Miami

37167

Advancing Vision Research LLC, Smyrna

37411

Chattanooga Eye Institute, Chattanooga

38119

Novartis Investigative Site, Memphis

48105

Univ of MI Kellogg Eye Center ., Ann Arbor

58103

Bergstrom Eye Research LLC, Fargo

77025

Novartis Investigative Site, Houston

77030

Novartis Investigative Site, Houston

77074

Novartis Investigative Site, Houston

78738

Lake Travis Eye and Laser Ctr, Lakeway

84117

Stacy R Smith MD PC, Salt Lake City

91345

North Valley Eye Medical Group, Mission Hills

92122

Gordon Schanzlin New Vision Inst, San Diego

92660

NVISION Eye Centers, Newport Beach

94303

Stanford Eye Laser Center, Palo Alto

98057

Rainier Clinical Research Center Inc ., Renton

98119

Periman Eye Institute, Seattle

02111

Tufts Medical Center, Boston

02494

Boston Sight, Needham

060 8648

Novartis Investigative Site, Sapporo

141-0022

Novartis Investigative Site, Shinagawa

B75 6QW

Novartis Investigative Site, Birmingham

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY